Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project
A pandemic outbreak of COVID-19 has been sweeping the world since December. Some clinical trials are testing biological drugs to limit immune system dysregulation. The study reviewed all evidence documenting any involvement of the NO-cGMP-PDE5 axis. .Evidence suggests that PDE5 inhibitors could offer a new strategy in managing COVID-19. They could be counteracting the Ang-II-mediated downregulation of the AT-1 receptor.
